Compare PMEC & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMEC | NERV |
|---|---|---|
| Founded | 1984 | 2007 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.4M | 166.4M |
| IPO Year | 2021 | 2014 |
| Metric | PMEC | NERV |
|---|---|---|
| Price | $0.55 | $3.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.33 |
| AVG Volume (30 Days) | 105.2K | ★ 116.0K |
| Earning Date | 07-24-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,175,600.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.31 | $2.24 |
| 52 Week High | $2.44 | $12.46 |
| Indicator | PMEC | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 52.31 | 38.74 |
| Support Level | $0.50 | N/A |
| Resistance Level | $0.81 | $4.73 |
| Average True Range (ATR) | 0.09 | 0.25 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 47.35 | 37.32 |
Primech Holdings Ltd is a Singapore-based facilities services and AI robotics group with operations in Singapore and Hong Kong. Through its subsidiaries, the company provides integrated facilities management, cleaning and stewarding services to the public and private sectors, serving airports, educational institutions, healthcare facilities, commercial buildings and hospitality venues. It also develops HYTRON, an autonomous restroom-cleaning robot that uses AI perception and robotic manipulation. In addition, the company operates HomeHelpy, a digital platform for booking home services for consumers.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.